Close Menu

NEW YORK (GenomeWeb) – Clovis Oncology has partnered with Myriad Genetics to meet a post-marketing requirement for its PARP inhibitor Rubraca (rucaparib).

Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the US Food and Drug Administration originally approved in December 2014 alongside AstraZeneca's PARP inhibitor Lynparza (olaparib). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.